Clinical trial
Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Repeated Doses of SAR156597 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT01529853 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Repeated Doses of SAR156597 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Sanofi
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 31, 2012
- Completion date
- October 31, 2013
- Enrollment
- 24 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.